Objective: The objective of this study was tocompare 1-year total healthcare costs for patientswith overactive bladder (OAB) initiating treatmentwith extended-release formulations of tolterodineand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback